Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Swain, D. Miles, Sung-Bae Kim, Y. Im, S. Im, V. Semiglazov, E. Ciruelos, A. Schneeweiss, S. Loi, E. Monturus, E. Clark, A. Knott, E. Restuccia, M. Benyunes, J. Cortés (2020)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.The Lancet. Oncology
W. Lai, L. Lebas, T. Barnes, J. Milia, A. Ni, O. Gautschi, S. Peters, R. Ferrara, A. Plodkowski, J. Kavanagh, J. Sabari, S. Clarke, N. Pavlakis, A. Drilon, C. Rudin, M. Arcila, N. Leighl, F. Shepherd, M. Kris, J. Mazières, Bob Li (2019)
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.European journal of cancer, 109
(2018)
A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant nonsmall cell lung cancer (NSCLC)
Keunchil Park, Chong-Jen Yu, Sang Kim, Meng-Chih Lin, Meng-Chih Lin, V. Sriuranpong, C. Tsai, J. Lee, J. Kang, K. Chan, P. Perez-Moreno, P. Button, M. Ahn, T. Mok (2016)
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.JAMA oncology, 2 3
Bob Li, F. Michelini, S. Misale, E. Cocco, L. Baldino, Yanyan Cai, Sophie Shifman, H. Tu, Mackenzie Myers, Chongrui Xu, M. Mattar, I. Khodos, M. Little, Besnik Qeriqi, G. Weitsman, Clare Wilhelm, A. Lalani, I. Diala, R. Freedman, N. Lin, D. Solit, M. Berger, P. Barber, T. Ng, M. Offin, J. Isbell, David Jones, H. Yu, S. Thyparambil, W. Liao, A. Bhalkikar, F. Cecchi, D. Hyman, Jason Lewis, Darren Buonocore, A. Ho, V. Makker, J. Reis-Filho, P. Razavi, M. Arcila, M. Kris, J. Poirier, R. Shen, J. Tsurutani, G. Ulaner, E. Stanchina, N. Rosen, C. Rudin, M. Scaltriti (2020)
HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers.Cancer discovery
S. Peters, R. Stahel, L. Bubendorf, P. Bonomi, A. Villegas, D. Kowalski, C. Baik, D. Isla, J. Carpeño, P. Garrido, A. Rittmeyer, M. Tiseo, Christoph Meyenberg, S. Haas, L. Lam, Michael Lu, T. Stinchcombe (2018)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and BiomarkersClinical Cancer Research, 25
H. Yu, M. Arcila, N. Rekhtman, C. Sima, M. Zakowski, W. Pao, M. Kris, V. Miller, M. Ladanyi, Gregory Riely (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersClinical Cancer Research, 19
G. Minckwitz, K. Schwedler, Marcus Schmidt, J. Barinoff, C. Mundhenke, T. Čufer, E. Maartense, F. Jongh, K. Baumann, J. Bischoff, N. Harbeck, H. Lück, N. Maass, C. Zielinski, M. Andersson, R. Stein, V. Nekljudova, S. Loibl (2011)
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.European journal of cancer, 47 15
A. Fabi, G. Metro, G. Ferretti, D. Giannarelli, S. Cosimo, P. Papaldo, M. Mottolese, P. Carlini, A. Felici, M. Russillo, F. Cognetti (2008)
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.Breast, 17 5
T. Mok, Sang-We Kim, Yi-long Wu, K. Nakagawa, Jin-Ji Yang, M. Ahn, Jie Wang, Jie Yang, You Lu, S. Atagi, S. Ponce, Xiaojin Shi, Y. Rukazenkov, V. Haddad, K. Thress, J. Soria (2017)
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 36
K. Hotta, K. Aoe, T. Kozuki, K. Ohashi, K. Ninomiya, E. Ichihara, T. Kubo, T. Ninomiya, K. Chikamori, D. Harada, N. Nogami, T. Hirata, S. Hinotsu, S. Toyooka, K. Kiura (2017)
A Phase II Study of Trastuzumab Emtansine in HER2‐Positive Non–Small Cell Lung CancerJournal of Thoracic Oncology, 13
M. Jebbink, A. Langen, M. Boelens, K. Monkhorst, E. Smit (2020)
The force of HER2 - A druggable target in NSCLC?Cancer treatment reviews, 86
L. Gandhi, R. Bahleda, S. Tolaney, E. Kwak, J. Cleary, S. Pandya, A. Hollebecque, R. Abbas, R. Ananthakrishnan, A. Berkenblit, M. Krygowski, Yali Liang, K. Turnbull, G. Shapiro, J. Soria (2014)
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 2
Zhe-feng Liu, Lin Wu, Jun Cao, Zhe Yang, Chengzhi Zhou, Liming Cao, Hao Wu, Hai-bo Shen, M. Jin, Yong Zhang, X. Mao, J. Xiang, K. Ma, Bing Li, Tengfei Zhang, Yi Hu (2018)
Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patientsOncoTargets and therapy, 11
M. Kris, D. Camidge, G. Giaccone, T. Hida, Bob Li, J. O'Connell, I. Taylor, H. Zhang, M. Arcila, Z. Goldberg, P. Jänne (2015)
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.Annals of oncology : official journal of the European Society for Medical Oncology, 26 7
S. Peters, A. Curioni-Fontecedro, H. Nechushtan, J. Shih, W. Liao, O. Gautschi, V. Spataro, M. Unk, J. Yang, R. Lorence, P. Carrière, A. Cseh, G. Chang (2018)
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use ProgramJournal of Thoracic Oncology, 13
G. O’Kane, T. Barnes, N. Leighl (2018)
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.Current oncology, 25 Suppl 1
J. Heymach, M. Negrão, J. Robichaux, B. Carter, A. Patel, M. Altan, D. Gibbons, F. Fossella, G. Simon, V. Lam, G. Blumenschein, A. Tsao, J. Kurie, F. Mott, Dennis Jenkins, D. Mack, Lei Feng, B. Roeck, Z. Yang, V. Papadimitrakopoulou, Y. Elamin (2018)
OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)Journal of Thoracic Oncology
(2020)
258–65
J. Grève, T. Morán, M. Graas, D. Galdermans, P. Vuylsteke, J. Canon, D. Schallier, L. Decoster, E. Teugels, D. Massey, V. Chand, J. Vansteenkiste (2015)
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.Lung cancer, 88 1
R. Dziadziuszko, E. Smit, U. Dafni, J. Wolf, B. Wasąg, W. Biernat, S. Finn, R. Kammler, Z. Tsourti, M. Rabaglio, B. Ruepp, H. Roschitzki-Voser, R. Stahel, E. Felip, S. Peters (2019)
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14 6
J. Rothenstein, N. Chooback (2018)
ALK inhibitors, resistance development, clinical trials.Current oncology, 25 Suppl 1
Bob Li, D. Ross, D. Aisner, J. Chaft, M. Hsu, S. Kako, M. Kris, M. Varella-Garcia, M. Arcila (2016)
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung CancersJournal of Thoracic Oncology, 11
J. Mazières, F. Barlesi, T. Filleron, B. Besse, I. Monnet, M. Beau-Faller, S. Peters, É. Dansin, M. Früh, M. Pless, R. Rosell, M. Wislez, P. Fournel, V. Westeel, F. Cappuzzo, A. Cortot, D. Moro-Sibilot, J. Milia, O. Gautschi (2016)
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Annals of oncology : official journal of the European Society for Medical Oncology, 27 2
E. Jordan, H. Kim, M. Arcila, D. Barron, D. Chakravarty, Jianjiong Gao, Matthew Chang, A. Ni, Ritika Kundra, P. Jonsson, G. Jayakumaran, S. Gao, Hannah Johnsen, Aphrothiti Hanrahan, A. Zehir, N. Rekhtman, M. Ginsberg, Bob Li, H. Yu, P. Paik, A. Drilon, M. Hellmann, D. Reales, R. Benayed, V. Rusch, M. Kris, J. Chaft, J. Baselga, B. Taylor, N. Schultz, C. Rudin, D. Hyman, M. Berger, D. Solit, M. Ladanyi, Gregory Riely (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Cancer discovery, 7 6
M. Davidson, N. Starling (2016)
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesOncoTargets and therapy, 9
J. Tsurutani, H. Iwata, I. Krop, P. Jänne, T. Doi, S. Takahashi, Haeseong Park, C. Redfern, K. Tamura, T. Wise-Draper, K. Saito, M. Sugihara, J. Singh, Takahiro Jikoh, G. Gallant, Bob Li (2020)
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.Cancer discovery
(Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol 2020; 38(suppl; abstr 9504).)
Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol 2020; 38(suppl; abstr 9504).Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol 2020; 38(suppl; abstr 9504)., Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol 2020; 38(suppl; abstr 9504).
K. Ninomiya, T. Hata, H. Yoshioka, K. Ohashi, A. Bessho, S. Hosokawa, N. Ishikawa, M. Yamasaki, T. Shibayama, K. Aoe, T. Kozuki, S. Harita, Y. Ueda, T. Murakami, N. Fujimoto, H. Yanai, S. Toyooka, M. Takata, K. Hotta, K. Kiura (2019)
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).Chest
C. Rolfo, P. Mack, G. Scagliotti, P. Baas, F. Barlesi, T. Bivona, R. Herbst, T. Mok, N. Peled, R. Pirker, L. Raez, M. Reck, J. Riess, L. Sequist, F. Shepherd, L. Sholl, D. Tan, H. Wakelee, I. Wistuba, M. Wynes, D. Carbone, F. Hirsch, D. Gandara (2018)
Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCJournal of Thoracic Oncology, 13
I. Oh, J. Hur, Cheol-Kyu Park, Young-chul Kim, S. Kim, M. Lee, Hee-Joung Kim, K. Lee, Jae Lee, Chang-Min Choi (2018)
Clinical Activity of Pan‐HER Inhibitors Against HER2‐Mutant Lung AdenocarcinomaClinical Lung Cancer, 19
J. Hainsworth, F. Meric-Bernstam, C. Swanton, H. Hurwitz, D. Spigel, C. Sweeney, H. Burris, R. Bose, B. Yoo, A. Stein, M. Beattie, R. Kurzrock (2018)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 6
Jessica Lin, A. Schoenfeld, V. Zhu, B. Yeap, E. Chin, M. Rooney, A. Plodkowski, S. Digumarthy, I. Dagogo-Jack, J. Gainor, S. Ou, Gregory Riely, A. Shaw (2020)
Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
E. Smit, K. Nakagawa, M. Nagasaka, E. Felip, Y. Goto, Bob Li, J. Pacheco, H. Murakami, F. Barlesi, A. Saltos, M. Pérol, H. Udagawa, K. Saxena, R. Shiga, F. Guevara, S. Acharyya, J. Shahidi, D. Planchard, P. Jänne (2020)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.Journal of Clinical Oncology, 38
Yan Wang, T. Jiang, Z. Qin, J. Jiang, Q. Wang, Shuo Yang, C. Rivard, G. Gao, T. Ng, M. Tu, M. Tu, Hui Yu, H. Ji, H. Ji, Caicun Zhou, S. Ren, S. Ren, Jun Zhang, P. Bunn, R. Doebele, D. Camidge, F. Hirsch (2019)
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibAnnals of Oncology, 30
David Hyman, S. Piha-Paul, H. Won, J. Rodón, C. Saura, Geoffrey Shapiro, D. Juric, David Quinn, V. Moreno, B. Doger, Ingrid Mayer, V. Boni, E. Calvo, S. Loi, A. Lockhart, J. Erinjeri, M. Scaltriti, G. Ulaner, J. Patel, Jiabin Tang, H. Beer, S. Selcuklu, Aphrothiti Hanrahan, N. Bouvier, Myra Melcer, R. Murali, A. Schram, L. Smyth, K. Jhaveri, Bob Li, A. Drilon, James Harding, G. Iyer, Barry Taylor, Michael Berger, R. Cutler, Feng Xu, A. Butturini, L. Eli, G. Mann, C. Farrell, A. Lalani, R. Bryce, Carlos Arteaga, F. Meric-Bernstam, J. Baselga, D. Solit (2018)
HER kinase inhibition in patients with HER2- and HER3-mutant cancersNature, 554
S. Ou, P. Jänne, C. Bartlett, Y. Tang, D-W. Kim, G. Otterson, L. Crinò, P. Selaru, D. Cohen, J. Clark, Gregory Riely (2014)
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.Annals of oncology : official journal of the European Society for Medical Oncology, 25 2
Oncogene-addicted non-small cell lung cancer (NSCLC) comprises a number of distinct disease subtypes, each of which is characterised by druggable genetic alterations. Among them, the receptor tyrosine kinase protein human epidermal receptor 2 (HER2) is occasionally found deregulated via gene mutation and/or amplification and/or protein overexpression. HER2 mutation, in particular, is a relatively rare condition which occurs in 1–4% of NSCLC patients, especially in those with adenocarcinoma histology and a never/light smoking history. However, the clinical relevance of a HER2 mutation in NSCLC relies on the fact that this genetic alteration has been associated with sensitivity to anti-HER2 therapies such as the monoclonal antibody trastuzumab or the pan-HER-tyrosine kinase inhibitor poziotinib. Here we describe the case of a NSCLC patient with an activating exon 20 G776VinsC mutation in the HER2 gene who responded well to multiple lines of trastuzumab-based therapies administered beyond progression and poziotinib given sequentially. In this specific case, the discovery of a druggable genetic alteration such as a mutation in the HER2 gene allowed for long-term control of the disease through the use of highly effective anti-HER2 therapies.
Oncology and Therapy – Springer Journals
Published: Jul 7, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.